Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03081689 | Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients | completed | Phase 2 | 46 | Spanish Lung Cancer GroupOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05807893 |
| Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases(SUPER BRAIN) |
| completed |
| Phase 2 / Phase 3 |
| 40 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| Nov 13, 2024 |
| clinicaltrials |
| NCT05048082 | A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies | completed | Phase 2 | 24 | OncoNano Medicine, Inc.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT05898763 | TEIPP Immunotherapy in Patients With NSCLC(TEIPP) | completed | Phase 1 / Phase 2 | 26 | Erasmus Medical CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT02094261 | Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours(AURA2) | completed | Phase 2 | 210 | AstraZenecaINDUSTRY | 8 | Nov 6, 2024 | clinicaltrials |
| NCT00309998 | Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 50 | University of RochesterOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT04952597 | Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer | completed | Phase 2 | 126 | BeiGeneINDUSTRY | 3 | Oct 26, 2024 | clinicaltrials |
| NCT01725165 | Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 85 | M.D. Anderson Cancer CenterOTHER | 2 | Oct 24, 2024 | clinicaltrials |
| NCT03486730 | BT1718 in Patients with Advanced Solid Tumours. | completed | Phase 1 / Phase 2 | 72 | Cancer Research UKOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03217071 | Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer | completed | Phase 2 | 12 | Sue YomOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03293680 | Pembrolizumab in Elderly Patients With Advanced Lung Cancer | completed | Phase 2 | 83 | Spanish Lung Cancer GroupOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03432598 | Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer | completed | Phase 2 | 54 | BeiGeneINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03958045 | Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | completed | Phase 2 | 33 | Zhonglin HaoOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT05400226 | Phase 2 Study of VGT-309 in Lung Cancer | completed | Phase 2 | 40 | Vergent Bioscience, Inc.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03004183 | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC(STOMP) | completed | Phase 2 | 57 | The Methodist Hospital Research InstituteOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05383898 | Study to Evaluate D-1553 in Subjects With Lung Cancer | completed | Phase 1 / Phase 2 | 225 | InventisBio Co., LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT02955758 | Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer | completed | Phase 2 | 25 | Joel NealOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03526900 | Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis(ATEZO-BRAIN) | completed | Phase 2 | 40 | Spanish Lung Cancer GroupOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03583086 | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | completed | Phase 1 / Phase 2 | 88 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03822351 | Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC(COAST) | completed | Phase 2 | 189 | MedImmune LLCINDUSTRY | 9 | Oct 8, 2024 | clinicaltrials |
| NCT01306045 | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | completed | Phase 2 | 647 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04768296 | Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) | completed | Phase 2 | 76 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 7 | Sep 26, 2024 | clinicaltrials |
| NCT02264210 | Icotinib for Completed Resected IB NSCLC With EGFR Mutation(CORIN) | completed | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT03565003 | A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China | completed | Phase 1 / Phase 2 | 126 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT00686985 | Docetaxel - Carboplatin As Second Line Treatment in Patients with Small Cell Lung Cancer(DOCAR) | completed | Phase 2 | 50 | Dr. B. BiesmaOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT02250326 | Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer(abound2L+) | completed | Phase 2 | 240 | CelgeneINDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT02855125 | A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 | completed | Phase 2 | 128 | Taiho Oncology, Inc.INDUSTRY | 6 | Sep 19, 2024 | clinicaltrials |
| NCT02927301 | A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3) | completed | Phase 2 | 181 | Genentech, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04167657 | SinTilimab After Radiation (STAR Study)(STAR) | completed | Phase 2 | 14 | Peking Union Medical College HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04434482 | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 59 | Impact Therapeutics, Inc.INDUSTRY | 5 | Sep 19, 2024 | clinicaltrials |
| NCT04721223 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 12 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT00651833 | Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 60 | Taiho Oncology, Inc.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT00652561 | Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 57 | Taiho Oncology, Inc.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT02664181 | Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial(PRECISE) | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT03971474 | Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) | completed | Phase 2 | 166 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04173507 | Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) | completed | Phase 2 | 47 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 3, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03473925 | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | completed | Phase 2 | 107 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 28, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT03664024 | Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)(KEYNOTE-782) | completed | Phase 2 | 118 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 22, 2024 | clinicaltrials |
| NCT02420314 | Pharmacological Ascorbate for Lung Cancer | completed | Phase 2 | 55 | Joseph J. Cullen, MD, FACSOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT04764214 | SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs | completed | Phase 2 | 61 | Fudan UniversityOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT04770688 | Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib(AUTOMAN) | completed | Phase 1 / Phase 2 | 25 | Shanghai Chest HospitalOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT02773238 | FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging | completed | Phase 2 | 51 | University of WashingtonOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT01970865 | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | completed | Phase 1 / Phase 2 | 364 | PfizerINDUSTRY | 14 | Aug 12, 2024 | clinicaltrials |
| NCT04144608 | Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC(TOGATHER) | completed | Phase 2 | 40 | Yongchang ZhangOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03417895 | SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy(PASSION) | completed | Phase 2 | 59 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05068427 | Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. | completed | Phase 2 | 34 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 4, 2024source: clinicaltrials